AIM ImmunoTech Files Q1 2025 10-Q
Ticker: AIM · Form: 10-Q · Filed: May 15, 2025 · CIK: 946644
Sentiment: neutral
Topics: 10-Q, biotech, financials, preferred-stock
Related Tickers: AIMI
TL;DR
AIM ImmunoTech's Q1 2025 10-Q is in. Details on preferred stock and financials are here.
AI Summary
AIM ImmunoTech Inc. filed its 10-Q for the period ending March 31, 2025. The company, formerly Hemispherx Biopharma Inc., is focused on biological products. Key financial data and stock information, including Series A and Series B preferred stock, are detailed in the filing.
Why It Matters
This filing provides investors with the latest financial performance and operational updates for AIM ImmunoTech, a company in the biological products sector.
Risk Assessment
Risk Level: medium — Biotech companies often carry higher risk due to the nature of drug development and regulatory hurdles.
Key Numbers
- 2025-03-31 — Reporting Period End Date (Indicates the end of the financial quarter covered by the report.)
- 2025-05-15 — Filing Date (The date the 10-Q was officially submitted to the SEC.)
Key Players & Entities
- AIM ImmunoTech Inc. (company) — Filer of the 10-Q
- Hemispherx Biopharma Inc. (company) — Former name of AIM ImmunoTech Inc.
- 20250331 (date) — End of the reporting period
- 20250515 (date) — Filing date
- SeriesAJuniorParticipatingPreferredStockMember (stock) — Type of preferred stock mentioned
- SeriesBConvertiblePreferredStockMember (stock) — Type of preferred stock mentioned
FAQ
What is the primary business of AIM ImmunoTech Inc.?
AIM ImmunoTech Inc. is primarily involved in biological products, specifically excluding diagnostic substances, as indicated by its SIC code [2836].
What was the previous name of AIM ImmunoTech Inc.?
AIM ImmunoTech Inc. was formerly known as Hemispherx Biopharma Inc., with a name change occurring on June 14, 1995.
For which fiscal period is this 10-Q filing?
This 10-Q filing is for the first quarter of the fiscal year ending March 31, 2025.
What types of preferred stock are mentioned in the filing data?
The filing data mentions Series A Junior Participating Preferred Stock and Series B Convertible Preferred Stock.
Where is AIM ImmunoTech Inc. headquartered?
AIM ImmunoTech Inc.'s business and mailing address is located at 2117 SW Highway 484, Ocala, Florida, 32801.
Filing Details
This Form 10-Q (Form 10-Q) was filed with the SEC on May 15, 2025 regarding AIM ImmunoTech Inc. (AIM).